The U.S. economy grew at a solid 3.9 percent annual rate in the July-September period, even faster than first reported, giving the country its strongest six months of growth in more than a decade.
Spark Therapeutics has announced today appointment of Daniel M. Takefman, Ph.D., as head of...
Consumers across most of America will see their health insurance premiums go up next year for...
Cocrystal Pharma, a biotechnology company developing novel antiviral therapeutics for human...
Mylan has confirmed that it and several subsidiaries have been sued by several Baxter subsidiaries in connection with the filing of an Abbreviated New Drug Application (ANDA) with the FDA for Esmolol HCl in Sodium Chloride Injection.
BMS and Five Prime Therapeutics to Evaluate Investigational Immunotherapies Opdivo and FPA008 in Six Tumor TypesNovember 24, 2014 4:09 pm | News | Comments
Bristol-Myers Squibb Company and Five Prime Therapeutics have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo, Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, with FPA008, Five Prime’s monoclonal antibody that inhibits colony stimulating factor-1 receptor.
Amgen is ending late-stage trials of its gastric cancer treatment rilotumumab because patients who took the drug were more likely to die. Amgen said more patients died after treatment with rilotumumab and chemotherapy than with chemotherapy alone.
Zoetis today announced the appointment of Roman Trawicki as President of its Global Manufacturing and Supply organization.
The next Ebola or the next SARS. Maybe even the next HIV. Even before the Ebola epidemic in West Africa is brought under control, public health officials are girding for the next health disaster.
AstraZeneca has announced plans to expand its biologics manufacturing center in Frederick, Md. The more than $200M project will increase production capacity at the facility to support AstraZeneca’s maturing pipeline, and will help position the company to keep pace with a growing demand for the development and use of biologics, which currently represent nearly 50% of AstraZeneca’s overall pipeline.
Google paid $500 million to settle a U.S. Justice Department investigation that alleged the company's top executives allowed ads for illegal pharmaceutical drugs to be distributed through its marketing network. Yet it is far and away the leader in online search and owns other widely used services such as Android and Chrome.
In a big year for deal making, the health care industry is a standout. Large drugmakers are buying and selling businesses to control costs and deploy surplus cash. A rising stock market, tax strategies and low interest rates are also fueling the mergers and acquisitions.
Merck and NewLink Genetics Corporation have entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink’s investigational rVSV-EBOV (Ebola) vaccine candidate.
Rigel Pharmaceuticals today announced James M. Gower is retiring from the board of directors and from his positions as chairman and chief executive officer, and Raul Rodriguez, most recently serving as the company's president and chief operating officer, will assume the position of chief executive officer and join the board of directors.
BioMarin Pharmaceutical will pay $680 million in cash for the Dutch biotech company Prosensa in a bid to strengthen its pipeline of genetic disorder treatments.
As the population ages and more people live longer with chronic medical conditions — for instance, the number of Americans with Alzheimer's disease is expected to nearly triple by 2050 — companies are beginning to grapple with growing numbers of workers who have elder-care responsibilities.
New research finds that the costs of diabetes care and lost productivity due to the condition totaled $322 billion in 2012. Also, new warnings about hookah smoke.
A New York couple who said Botox treatment of their son's cerebral palsy left him with life-threatening complications and sued its manufacturer won a $6.75 million verdict from a federal jury on Thursday.
A German federal court has ruled that the liquids contained in e-cigarettes aren't medicinal products and can be sold freely.
Anthera Pharmaceuticals has signed a manufacturing and supply agreement with the Patheon division of DPx Holdings B.V. The contract provides for Patheon to support the production of the Sollpura clinical drug product for Anthera's Phase III registration trial.
The average cost of developing an approved therapy is around $4.3 billion dollars for companies with three or more approved therapies, according to an analysis completed by Forbes. Imagine, then, our surprise when we discovered a biotechnology company outside of New York City that had developed three approved therapies for an average cost of $0.7 billion dollars – less than 20 percent of the industry average.
The Cystic Fibrosis Foundation says it has sold royalty rights worth $3.3B for innovative drugs it helped develop with Vertex Pharmaceuticals. The drug rights were acquired by Royalty Pharma, which owns royalty rights to 40 pharmaceutical medicines.
Vetter has announced the opening of a new representative office in Singapore. The announcement was made at a ceremony attended by members of local government agencies and a number of executives of pharmaceutical/biotech companies with a presence in the Asian region, as well as Vetter executives.
Some low-cost generic drugs that have helped restrain health care costs for decades are seeing unexpected price spikes of up to 8,000 percent, prompting a backlash from patients, pharmacists and now Washington lawmakers.
A new report by the McKinsey Global Institute says that the global cost of obesity has risen to $2 trillion annually — nearly as much as smoking or the combined impact of armed violence, war and terrorism.
Apellis Pharmaceuticals has entered into an agreement to acquire Potentia Pharmaceuticals. As part of the acquisition agreement, Apellis obtained the necessary intellectual property rights to develop its complement inhibitor drug compound (APL-2) in ophthalmology and plans its first clinical trial in dry age-related macular degeneration.
Shire has announced plans to relocate over 500 positions to Massachusetts from its Chesterbrook, Pennsylvania site and establish Lexington, Massachusetts as the company's U.S. operational headquarters. The transition is a continuation of the company's 'One Shire' efficiency program and will streamline business globally through two principal locations - Massachusetts and Switzerland.
The pharmaceutical market is beginning to show signs of stability, with a review of 30 leading companies highlighting combined revenues of $718.7 billion in 2013, down just 0.2% from 2012, according to research and consulting firm GlobalData.
Developing a new prescription medicine that gains marketing approval, a process often lasting longer than a decade, is estimated to cost $2,558 million, according to a new study by the Tufts Center for the Study of Drug Development.
- Page 1